Loading clinical trials...

Relationship Between Serum 1,25-dihydroxy Vitamin D and Markers of Bone Metabolism in Renal Dysfunction Patients | Clinical Trials | Clareo Health

COMPLETED

Relationship Between Serum 1,25-dihydroxy Vitamin D and Markers of Bone Metabolism in Renal Dysfunction Patients

NCT05399251•Aga Khan University Hospital, Pakistan

View on ClinicalTrials.gov

Summary

This cross-sectional study was conducted, including those subjects tested for 1,25(OH)2D during Jan 2015-Dec 2021. Estimated glomerular filtration rate (eGFR) was calculated and subjects were classified into chronic kidney disease (CKD) stages. Associations between biochemical marker, calcium, phosphorus, magnesium, alkaline phosphatase, 1,25(OH)2D and CKD stages was determined.

Eligibility

Age

20 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Data of serum 1,25(OH)2D available

Exclusion Criteria

•Serum1,25(OH)2D is not available

Key Dates

Start Date

January 1, 2015

Primary Completion Date

December 30, 2021

Completion Date

December 30, 2021

Last Updated

June 1, 2022

Enrollment

1,553

ACTUAL participants

Conditions

Chronic Kidney Disease-Mineral and Bone Disorder

Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease

NCT04522622

Adynamic Bone DiseaseChronic Kidney Diseases+2 more

View study

RECRUITING

Integrated Diagnosis and Treatment of CKD on Outcomes

NCT05242055

Chronic Kidney DiseasesHypertension+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 1, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Relationship Between Serum 1,25-dihydroxy Vitamin D and Markers of Bone Metabolism in Renal Dysfunction Patients

Inclusion Criteria

Exclusion Criteria

Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease

Integrated Diagnosis and Treatment of CKD on Outcomes

DePTH: De-emphasize PTH

To Investigate the Bone and Muscle Abnormalities in Patients With Chronic Kidney Disease With MRI